Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 4 (50%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 2 | 50.8% | +61.7% |
| SANKS, SCHYLER S | 1 | 72.9% | +15.9% |
| TRAN, CHRISTINA L | 1 | 51.6% | +49.8% |
| WILSON, JERICA KATLYNN | 1 | 60.5% | +39.8% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +28.6% |
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | WILSON, JERICA KATLYNN | 7d |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | — |
| 18565733 | ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR) | TRAN, CHRISTINA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | WILSON, JERICA KATLYNN | 7d |
| 19223597 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING | PERSONS, JENNA L | 8d |
| 17924066 | MODULATION OF MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN SIGNALING | CARTER, SANDRA DILLAHUNT | 70d |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 70d |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | — |
| 18565733 | ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR) | TRAN, CHRISTINA L | — |
| 18035082 | TARGET-CELL RESTRICTED, COSTIMULATORY, BISPECIFIC AND BIVALENT ANTI-CD28 ANTIBODIES | DRISCOLL, MAUREEN VARINA | — |
| 18071999 | ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR) | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 3 |
| 1674 | 2 |
| 2129 | 1 |
| 1621 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19223597 | CHEMICALLY MODIFIED ANTISENSE OLIGONUCLEOTIDES (ASOS) AND COMPOSITIONS COMPRISING THE SAME FOR RNA EDITING | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | 8d | Pending | May 30, 2025 |
| 18578680 | ATOMIC QUANTUM PROCESSOR | SANKS, SCHYLER S | 2129 | §103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18565733 | ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR) | TRAN, CHRISTINA L | 1637 | §102§103 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18035671 | PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | WILSON, JERICA KATLYNN | 1621 | §102§103 | Final Rejection | 7d | Pending | May 05, 2023 |
| 18035082 | TARGET-CELL RESTRICTED, COSTIMULATORY, BISPECIFIC AND BIVALENT ANTI-CD28 ANTIBODIES | DRISCOLL, MAUREEN VARINA | 1644 | §112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18071999 | ANTISENSE OLIGONUCLEOTIDES (ASO) FOR EFFICIENT AND PRECISE RNA EDITING WITH ENDOGENOUS ADENOSINE DEAMINASE ACTING ON RNA (ADAR) | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | — | Pending | Nov 30, 2022 |
| 17924066 | MODULATION OF MIXED LINEAGE KINASE DOMAIN-LIKE PROTEIN SIGNALING | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Non-Final OA | 70d | Pending | Nov 08, 2022 |
| 17777975 | ANTIBODIES TARGETING, AND OTHER MODULATORS OF, THE CD276 ANTIGEN, AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §102§112 | Final Rejection | 70d | Pending | May 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEBERHARD KARLS UNIVERSITÄT TÜBINGEN has 8 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Jenna L Persons has the most, with 2 of EBERHARD KARLS UNIVERSITÄT TÜBINGEN's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
